radioisotopes moderate essential conventional radioimmunotherapy using mabs require days localization NUMBER days yield NUMBER alpha particles decay chain ideal choice radioimmunotherapy release daughter radioisotopes primary chelator decay complication use 225ac reported product mab cc49 ch2 cc49 able extravasate penetrate deeply tumors parent igg molecule reasoned penetrated tumor daughter radioisotopes remain trapped released primary chelator heha mab cc49 conjugates tested distribution therapy immunocompromised mice ls174t tumors growing subcutaneous intramuscular sites 125i 225ac cc49 ch2 cc49 efficient delivery radioisotopes tumor sites tissue antibody forms did demonstrate differences 125i 225ac tumor furthermore detectable difference carriers tumor retention daughter radioisotopes 225ac therapy experiments 225ac complicated radiotoxicity conjugates lethal dose NUMBER microci strains mice regardless carrier injected doses NUMBER NUMBER microci cc49 slightly active tumor stasis consistent significant effect ch2 cc49 growth tumors observed potential 225ac radioimmunotherapy limited radiotoxicity daughter radioisotopes potential realized stable conjugates capable daughter radioisotope retention devised half lives tumor selective actinium NUMBER half life tumor targeted domain deleted hu delta 225ac chelate mab actinium NUMBER micro distribution hu delta micro autoradiography micro distribution 225ac hu delta